These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31540711)

  • 1. Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis.
    Johnen A; Elpers C; Riepl E; Landmeyer NC; Krämer J; Polzer P; Lohmann H; Omran H; Wiendl H; Göbel K; Meuth SG
    Eur J Paediatr Neurol; 2019 Nov; 23(6):783-791. PubMed ID: 31540711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive deficits including executive functioning in relation to clinical parameters in paediatric MS patients.
    Wuerfel E; Weddige A; Hagmayer Y; Jacob R; Wedekind L; Stark W; Gärtner J
    PLoS One; 2018; 13(3):e0194873. PubMed ID: 29566099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological characteristics of benign multiple sclerosis patients: A two-year matched cohort study.
    Hegedüs K; Kárpáti J; Iljicsov A; Simó M
    Mult Scler Relat Disord; 2019 Oct; 35():150-155. PubMed ID: 31376686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).
    Johnen A; Bürkner PC; Landmeyer NC; Ambrosius B; Calabrese P; Motte J; Hessler N; Antony G; König IR; Klotz L; Hoshi MM; Aly L; Groppa S; Luessi F; Paul F; Tackenberg B; Bergh FT; Kümpfel T; Tumani H; Stangel M; Weber F; Bayas A; Wildemann B; Heesen C; Zettl UK; Zipp F; Hemmer B; Meuth SG; Gold R; Wiendl H; Salmen A;
    J Neurol; 2019 Feb; 266(2):386-397. PubMed ID: 30515631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    Bouman PM; van Dam MA; Jonkman LE; Steenwijk MD; Schoonheim MM; Geurts JJG; Hulst HE
    J Neurol; 2024 May; 271(5):2159-2168. PubMed ID: 38286843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis.
    Feinstein A; Meza C; Stefan C; Staines RW
    Brain; 2019 Sep; 142(9):2800-2812. PubMed ID: 31363742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.
    Mokhber N; Azarpazhooh A; Orouji E; Rao SM; Khorram B; Sahraian MA; Foroghipoor M; Gharavi MM; Kakhi S; Nikkhah K; Azarpazhooh MR
    J Neurol Sci; 2014 Jul; 342(1-2):16-20. PubMed ID: 24841321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T
    Louapre C; Govindarajan ST; Giannì C; Madigan N; Nielsen AS; Sloane JA; Kinkel RP; Mainero C
    Neuroimage Clin; 2016; 12():879-886. PubMed ID: 27872810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory treatments and cognition in MS.
    Mückschel M; Beste C; Ziemssen T
    Acta Neurol Scand; 2016 Sep; 134 Suppl 200():55-9. PubMed ID: 27580907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective effects of high-education levels on cognition in different stages of multiple sclerosis.
    Rimkus CM; Avolio IMB; Miotto EC; Pereira SA; Mendes MF; Callegaro D; Leite CDC
    Mult Scler Relat Disord; 2018 May; 22():41-48. PubMed ID: 29554549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Wojcik C; Fuchs TA; Tran H; Dwyer MG; Jakimovski D; Unverdi M; Weinstock-Guttman B; Zivadinov R; Eshaghi A; Benedict RH
    Mult Scler; 2022 Mar; 28(3):463-471. PubMed ID: 33951975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of cognitive impairment in multiple sclerosis.
    Pierson SH; Griffith N
    Behav Neurol; 2006; 17(1):53-67. PubMed ID: 16720960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.
    Janardhan V; Bakshi R
    Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS).
    Charvet LE; Beekman R; Amadiume N; Belman AL; Krupp LB
    J Neurol Sci; 2014 Jun; 341(1-2):79-84. PubMed ID: 24792098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a.
    Menascu S; Aloni R; Dolev M; Magalashvili D; Gutman K; Dreyer-Alster S; Tarpin-Bernard F; Achiron R; Harari G; Achiron A
    J Neuroeng Rehabil; 2021 Dec; 18(1):175. PubMed ID: 34924009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study.
    Sabidó-Espin M; Munschauer R
    BMC Neurol; 2017 Mar; 17(1):57. PubMed ID: 28335743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gray matter networks and cognitive impairment in multiple sclerosis.
    Rimkus CM; Schoonheim MM; Steenwijk MD; Vrenken H; Eijlers AJ; Killestein J; Wattjes MP; Leite CC; Barkhof F; Tijms BM
    Mult Scler; 2019 Mar; 25(3):382-391. PubMed ID: 29320933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.